Jorn Drappa Net Worth

Jorn Drappa biography

Dr. Jorn Drappa M.D., Ph.D. serves as Chief Medical Officer, Head of Research and Development of the Company. Dr. Drappa brings more than two decades of experience in research and development in the inflammation and autoimmune therapeutic areas. Prior to joining us, Dr. Drappa served in various roles of increasing responsibility at MedImmune, the biologics division of AstraZeneca, our largest stockholder, since March 2011, most recently as Vice President, Clinical Development, where he headed the clinical functions of Respiratory, Inflammation, Autoimmune, Cardiovascular, Metabolic disease, and Infectious disease. Previously, Dr. Drappa served as Senior Medical Director for the Inflammation and Autoimmune assets at Genentech. Dr. Drappa received his medical degree, and a doctorate of medicine from the University of Cologne in Germany. He performed his postgraduate studies at Cornell Medical School/Hospital for Special Surgery, followed by residency at New York Hospital and Rheumatology fellowship at the Hospital for Special Surgery.

What is the salary of Jorn Drappa?

As the Chief Medical Officer a Head of Research and Development of Viela Bio, the total compensation of Jorn Drappa at Viela Bio is $1,651,150. There are 1 executives at Viela Bio getting paid more, with Zhengbin Yao having the highest compensation of $2,747,550.

How old is Jorn Drappa?

Jorn Drappa is 55, he's been the Chief Medical Officer a Head of Research and Development of Viela Bio since 2018. There are 3 older and 8 younger executives at Viela Bio. The oldest executive at Viela Bio, Inc. is Chris Nolet, 63, who is the Independent Director.

What's Jorn Drappa's mailing address?

Jorn's mailing address filed with the SEC is C/O ALPINE IMMUNE SCIENCES, INC., 188 EAST BLAINE STREET, SUITE 200, SEATTLE, WA, 98102.

Insiders trading at Viela Bio

Over the last 5 years, insiders at Viela Bio have traded over $58,712,400 worth of Viela Bio stock and bought 1,261,091 units worth $24,062,867 . The most active insiders traders include Andreas Wicki, Xiaomeng Tong a Plc Astra Zeneca Uk Ltd Ast.... On average, Viela Bio executives and independent directors trade stock every 41 days with the average trade being worth of $6,348. The most recent stock trade was executed by Aaron Ren on 18 November 2020, trading 2,000 units of VIE stock currently worth $5,680.

What does Viela Bio do?

Viela Bio, Inc., a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. It is also developing VIB4920 for kidney transplantation rejection and sjögren's syndrome; and VIB7734 for cutaneous lupus erythematosus. Viela Bio, Inc. has a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore, and Taiwan. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.

Viela Bio executives and stock owners

Viela Bio executives and other stock owners filed with the SEC include:

• Zhengbin Yao,
  Chairman of the Board, President, Chief Executive Officer
• Jorn Drappa,
  Chief Medical Officer, Head of Research and Development
• Mitchell Chan,
  Chief Financial Officer
• Aaron Ren,
  Vice President - Head of Business Development and Operations
• Chris Nolet,
  Independent Director
• Edward Hu,
  Independent Director
• Yanling Cao,
  Director
• Chad Rubin,
  IR Contact Officer
• Andreas Wicki,
  Independent Director
• Tyrell Rivers,
  Independent Director
• Rachelle Jacques,
  Independent Director
• Sean Tong,
  Director
• Jim Kastenmayer,
  General Counsel, Secretary
• William Ragatz,
  Vice President - Head of Commercial
• Xiaomeng Tong,
  Director
• Plc Astra Zeneca Uk Ltd Ast...,
  
• Meadow Ltd Boundless,
  10% owner
• James Paul Kastenmayer,
  General Counsel
• Meadow Ltd Boyu Capital Fun...,